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uvenile myoclonic epilepsy (JME; OMIM 606904) is a
subtype of common idiopathic generalised epilepsy (IGE)
and affects up to 26% of all individuals with IGE.1–3 JME is
characterised by the onset in adolescence of bilateral
myoclonic jerks usually affecting the upper limbs.1 4
Patients also have generalised tonic-clonic seizures and about
one third experience absence seizures. Genetic factors are
known to play an important role in the etiology of JME.3 4
While identification of genes underlying predisposition to
JME has been relatively slow due to clinical and genetic
heterogeneity,5 6 progress made so far in the isolation
and characterisation of genes associated with other mono-
genic subtypes of IGE, provides evidence that most
idiopathic epilepsy syndromes are caused by mutations in
genes encoding ion channels.7 The implications of these
findings in monogenic subtypes of the disorder for the
complex polygenic subset are now being increasingly
appreciated.8
Two types of voltage gated potassium channels have been
associated with seizure disorders, the KCNQ channels and
the Kv channels. Loss of function mutations for the
potassium channels KCNQ2 and KCNQ3 have been identified
in families with a rare autosomal dominant subtype of IGE
called benign familial neonatal convulsions (BFNC).9 10
Allelic association of JME with KCNQ3 has been suggested
in a South Indian cohort of JME patients.11 Mutation in
human KCN1A predisposes to episodic ataxia and partial
epilepsy.12 These findings emphasise the importance of
potassium channels in controlling neuronal excitability and
thus make potassium channel genes potentially interesting
candidates for idiopathic epilepsy syndromes.
The calcium activated potassium channels are an interest-
ing class of potassium channels that regulate neuronal
excitability.13 14 These are gated by intracellular calcium ions
and their activity is responsible in part for the afterpolarisa-
tion that follows a single action potential or a train of action
potentials in the neurons. According to their single channel
conductance in symmetrical potassium solutions, these
channels are classified13 14 as big (BK), intermediate (IK), or
small (SK). Biophysical and pharmacological analysis, single
cell mRNA, and protein expression profiling strongly suggest
that SK3 channels mediate the calcium dependent after-
hyperpolarisation in neurons.15 The neuronal small conduc-
tance calcium activated potassium channel (hSKCa3) plays a
critical role in determining the firing pattern of neurons
through the generation of slow afterhyperpolarisation16 17 and
regulation of intracellular calcium signals by binding with
calmodulin.18 In situ hybridisation in rat19 and human brain20
revealed that mRNAs encoding the SK family subunits are
widely expressed in the brain and show distinct but
overlapping patterns. These physiological attributes make
hSKCa3 an interesting candidate gene for investigation in an
IGE syndrome such as JME. While its role in schizophrenia
and bipolar disorders has been investigated,16 20–23 the
possibility of its influence on epilepsy phenotypes remains
poorly studied.
hSKCa316 encodes a 731 amino acid protein comprising two
polyglutamine arrays in its N terminus of which the second
polyglutamine repeat is highly polymorphic.16 We investi-
gated the length variation in the second polyglutamine
stretch of hSKCa3 and compared the allele frequency
distribution between 222 well characterised JME patients of
South Indian origin24 and 248 ethnically matched normal
subjects. Several genetic studies have been conducted on the
South Indian populations and it has been found that the
genetic distance between even the tribal populations is small,
signifying a close genetic relationship.25 Through this case-
control design, we intended to investigate whether variations
in the length of the expressed polyglutamine tract of hSKCa3
show allelic association with JME and thereby possibly
influence expression of the JME phenotype.
METHODS
Patients and controls
A total of 222 unrelated JME probands were recruited
through epilepsy centres situated in South India.24 Patient
samples were collected from specialty neurology clinics,
referral centres, and medical camps for seizure disorders
which were part of the rural outreach programs of the referral
centres. All the patients were unambiguously diagnosed cases
of JME with classification based on the published criteria of
the Commission on Classification and Terminology of the
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International League Against Epilepsy.2 A total of 248
subjects of South Indian origin without a family history of
epilepsy, ataxia, unexplained blackouts, or other chronic
neurological disorders were used as controls in this study. All
patients and controls provided written informed consent and
the study was approved by Institutional Bioethics Review
Board.
Genetic analysis
Genomic DNA was isolated from peripheral venous blood by
phenol-chloroform method. Polymerase chain reaction (PCR)
mediated amplification of the second polyglutamine CAG
tract of hSKCa3 was carried out in all subjects. Each reaction
comprised of 50 ng of genomic DNA, 20 pmol primers
(hSKCa3-F: 59-CAC CGT CAG TGT CAC CAG TAG TCC CC-
39 and hSKCa3-R: 59-Hex-GAA GGG GTT GCT GTC CCG CCG
GT-39),16 200 mM of each dNTP, 50 mM KCl, 10 mM Tris-HCl
(pH 8.3), 1.5 mM MgCl2, and 0.5 U Taq DNA polymerase in
10 ml final volume. Forty cycles of PCR were carried out, each
cycle with denaturation at 94 C˚ for 40 s, annealing at 52 C˚ for
40 s, and extension at 72 C˚ for 45 s.23 Genotyping was
performed by a person unaware of the affection status using
an ABI 3100 Genetic Analyzer (Applied Biosystems, Foster
City, CA). Allele sizing was done using Genotyper version 2.0
(Applied Biosystems).
Statistical analysis
Descriptive statistics were calculated for patient and control
data. Statistical tests were done as follows. Z tests of
proportions were computed in controls and cases in order
to obtain information on each individual allele. Relative risks
of the major alleles were calculated by computing the ratio of
presence and absence of each allele in the cases and controls.
Hardy-Weinberg equilibrium (HWE) was calculated in this
study to test for genotype frequencies, especially in the
control population as a measure to check for population
stratification or genotyping errors.
RESULTS
The mean (SD) age at onset of the JME probands was 14.9
(1.4) years. The triad of myoclonus, absences, and general-
ised tonic-clonic seizures was observed in 27.9%, the
combination of myoclonus and generalised tonic-clonic
seizures in 64.7%, and myoclonus alone in 7.4% of patients.
Of the patients 84% were receiving treatment with sodium
valproate. Scalp electroencephalogram (EEG) during wake-
fulness and sleep exhibited generalised epileptiform abnorm-
alities in about 70% of the patients, while 30% were seizure
free for 2 or more years and therefore exhibited normal EEG.
Clinical details of a large subset of these patients were
recently reported.24
Sixteen distinct hSKCa3 alleles were observed. Repeat size
ranged from 10 to 25. Thirteen alleles (CAG10–22) were seen
in the controls and 16 alleles (CAG10–25) were seen in the
patients. The frequency distribution of the observed alleles in
cases and controls is shown in fig 1. The modal repeat size
was CAG18. Statistical tests for alleles with a frequency .0.02
were carried out to find out if one or more of these allelic
variants showed significant frequency differences between
the control and the patient group. Z test of proportions for the
10 alleles (alleles with frequency less than 0.02 were
aggregated) was performed. In this analysis, the three alleles
CAG16 (0.018), CAG18 (0.019), and CAG19 (,0.00001) were
found to be significant. The distribution of CAG16 and CAG18
was higher in JME patients, while allele CAG19 was quite rare
in JME cases but present at a very high frequency in the
control group (table 1). When Bonferroni correction for
multiple testing (a at 0.005) was applied, only CAG19 was
found to be significant. Among the nine major alleles
(CAG13–21) observed, relative risk was found to be maximum
for allele CAG16 (1.198) and minimum for allele CAG19
(0.574) (table 2). We found the control population to be in
HWE at the 5% significance level (x2=0.0154, p=0.9012,
df=1), while the cases deviated from HWE at the 5%
significance level (x2= 5.5049, p=0.0189, df=1).
DISCUSSION
Genetic association studies are one of the useful approaches
to understanding the etiology of complex disorders.26
Increased or decreased allele or genotype frequencies in cases
or controls implicate sequence variants that either increase or
decrease the risk of a disease or are in strong linkage
disequilibrium with a disease causing mutation. The biolo-
gical effects of a specific risk or protective allele under study
are usually small.
We tested the association of JME with allelic variants at an
expressed polymorphic CAG repeat tract in a functionally
important calcium activated potassium channel gene
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Figure 1 hSKCa3 allele frequencies in cases and controls.
Table 1 Allele frequencies and pair-wise Z tests of JME cases and controls
CAGn Cases Controls p (cases) p (controls) Z value p Value
13 28 23 0.063 0.046 1.128 0.259
14 13 23 0.029 0.046 21.36316 0.1728
15 9 15 0.020 0.030 20.967 0.333
16 80 62 0.180 0.125 2.358 0.018
17 75 91 0.169 0.183 20.583 0.559
18 125 107 0.282 0.216 2.336 0.019
19 45 102 0.101 0.206 24.395 ,0.00001
20 40 43 0.090 0.087 0.1832 0.855
21 11 9 0.025 0.018 0.703 0.4819
Agg* 18 21 0.041 0.042 20.138 0.8902
CAGn, number of CAG repeats in the polymorphic marker alleles observed; p (case), frequency in cases; p (control), frequency in controls. Agg*, aggregate of
alleles with frequency less than 0.02.
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(hSKCa3). The allele CAG19 was found to be present at
significantly different frequencies in cases and controls,
implying its association with the JME phenotype. A previous
report from a German population investigated 126 IGE
patients (78 JME and 48 childhood absence epilepsy or
juvenile absence epilepsy cases) and found no evidence for
association between IGEs and hSKCa3.27 No evidence for
association between IGEs and hSKCa3 was found in this
study. We have obtained results which are different from this
published work. These differences are perhaps due to the use
of different ethnic populations, different sample sizes, or
differences in the subtypes of the clinical samples that were
studied. The sample size used in our study was comparatively
large and homogeneous and consisted only of JME cases of
South Indian origin and a control sample from the same
population. We found significant differences in the distribu-
tion of allele CAG16, CAG18, and CAG19 among South Indian
JME probands and ethnically matched control subjects.
These three alleles were significant without Bonferroni
correction. When this correction was applied, CAG19 was
the only allele found to be significant. However, we are
concerned about the astuteness of the Bonferroni correction
in this scenario as there is no logic in an a prior universal null
hypothesis for all the alleles tested or in the study
populations being identical on all the alleles analysed. This
point has been addressed by Perneger.28 Bonferroni adjust-
ments imply that a given comparison will be interpreted
differently according to how many other tests were
performed.
CAG16 and CAG18 were common while CAG19 was rare in
the JME patients studied. The relative risks due to CAG16,
CAG18, and CAG19 were found to be 1.198, 1.178, and 0.514,
respectively. The most probable role of CAG16, CAG18, and
CAG19 hSKCa3 variants may be in modulating the channel
function. Alternatively, the role of hSKCa3 may not be simply
as a numerical CAG counter. The possibility of additional
sequences within hSKCa3 that may influence the disease
phenotype cannot be ruled out. Additional polymorphisms in
the coding or regulatory regions of this complex gene that
spans about 163 kb and has a complex promoter with
binding sites for over 10 transcription factors may be
involved.29
Dynamic CAG repeat expansions have been implicated in
many neurological diseases. We did not observe a major
expansion in the CAG repeat polymorphism in the probands
studied. However, at least in two reported scenarios, CAG
repeat length polymorphisms within the normal reported
range have resulted in a disease state. These are Kennedy’s
disease30 and spinocerebellar ataxia type 6.31
We found observation of a possible protective effect on the
JME phenotype interesting. Protective alleles are important
modifiers of the phenotype. Unlike the alleles of susceptibility
genes that are over-represented in affected individuals
(cases) versus unaffected individuals (controls), protective
alleles occur preferentially in healthy individuals, implying
that their presence prevents disease despite the presence of
other disease promoting (susceptibility) alleles at the same
gene or genes elsewhere in the genome. Several reports have
highlighted the importance of protective alleles in various
disease conditions: deletion of CCR5 protects from HIV
infection,32 while HLA-DRB11 and HLA-DRQ03032 alleles
are both over-represented in controls versus breast cancer33
cases. In the light of these findings, our results on the hSKCa3
alleles suggest it should be carefully analysed further in JME
families.
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